Fetal Aneuploidy Confirmation Testing Market Report 2026

Fetal Aneuploidy Confirmation Testing Market Overview

• Fetal Aneuploidy Confirmation Testing market size has reached to $1.43 billion in 2025 • Expected to grow to $2.36 billion in 2030 at a compound annual growth rate (CAGR) of 10.6% • Growth Driver: Rising Maternal Age Driving The Market Growth Due To The Increasing Risk Of Chromosomal Abnormalities In Pregnancies Among Older Women • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Fetal Aneuploidy Confirmation Testing Market?

Fetal aneuploidy confirmation testing refers to diagnostic procedures used to verify the presence of chromosomal abnormalities in a fetus after an initial screening result indicates increased risk. These tests typically involve invasive methods such as amniocentesis or chorionic villus sampling to directly analyze fetal chromosomes. They provide definitive information about conditions including trisomy 21, trisomy 18, and trisomy 13 by examining the number and structure of chromosomes. The main test types of fetal aneuploidy confirmation testing include Non-invasive Prenatal Testing, invasive testing, and other test types. Non-invasive prenatal testing refers to methods that analyze cell-free fetal DNA from maternal blood to detect chromosomal abnormalities. The technologies include next-generation sequencing, polymerase chain reaction, fluorescence in situ hybridization, microarray, and other technologies. They find application in trisomy, sex chromosome aneuploidy, microdeletions, and other applications, serving end users including hospitals, diagnostic laboratories, specialty clinics, and other end users.

What Is The Fetal Aneuploidy Confirmation Testing Market Growth Forecast?

The fetal aneuploidy confirmation testing market size is expected to see rapid growth in the next few years. It will grow to $2.36 billion in 2030 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to increasing adoption of precision medicine approaches, growing integration of ai-based genetic analysis tools, rising demand for non-invasive prenatal testing confirmation, expansion of genomic research initiatives, increasing healthcare infrastructure investments in emerging markets. Major trends in the forecast period include increasing adoption of next-generation sequencing technologies, rising demand for early and accurate prenatal diagnosis, growing preference for confirmatory diagnostic testing after positive screening, expansion of advanced chromosomal microarray analysis, increasing availability of specialized prenatal diagnostic services.

Global Fetal Aneuploidy Confirmation Testing Market Segmentation

1) By Test Type: Non-Invasive Prenatal Testing, Invasive Testing, Other Test Types 2) By Technology: Next-Generation Sequencing, Polymerase Chain Reaction, Fluorescence In Situ Hybridization, Microarray, Other Technologies 3) By Application: Trisomy, Sex Chromosome Aneuploidy, Microdeletions, Other Applications 4) By End-User: Hospitals, Diagnostic Laboratories, Specialty Clinics, Other End Users Subsegments: 1) By Non-Invasive Prenatal Testing: Cell-Free Fetal Deoxyribonucleic Acid Testing, Maternal Serum Screening, Ultrasound-Based Risk Assessment, Next-Generation Sequencing-Based Non-Invasive Prenatal Testing, Chromosomal Microarray Analysis 2) By Invasive Testing: Amniocentesis, Chorionic Villus Sampling, Cordocentesis, Fetal Biopsy, Fetal Karyotyping 3) By Other Test Types: Preimplantation Genetic Testing, Targeted Gene Panels, Multiplex Polymerase Chain Reaction Testing, Fluorescence In Situ Hybridization Testing, Comparative Genomic Hybridization Testing

What Are The Drivers Of The Fetal Aneuploidy Confirmation Testing Market?

The rising maternal age is expected to propel the growth of the fetal aneuploidy confirmation testing market going forward. Maternal age refers to the age of a woman at the time she becomes pregnant or gives birth to a child. Maternal age is increasing due to women delaying childbirth to pursue higher education and focus on career development before starting a family. Fetal aneuploidy confirmation testing helps manage the risks associated with rising maternal age by accurately confirming chromosomal abnormalities that are more common in pregnancies among older women, enabling timely medical guidance and informed pregnancy decisions. For instance, in June 2025, according to the Centers for Disease Control and Prevention, a US-based government agency, the mean age of mothers at first birth increased from 27.4 years in 2022 to 27.5 years in 2023, reflecting an increase of 0.1 years. Therefore, rising maternal age is driving the growth of the fetal aneuploidy confirmation testing industry. The growth in personalized medicine is expected to propel the growth of the fetal aneuploidy confirmation testing market going forward. Personalized medicine is a medical approach that tailor’s prevention, diagnosis, and treatment strategies to an individual's unique genetic makeup, biomarkers, and molecular characteristics. Personalized medicine is rising due to rapid advances in genomic technologies and biomarker-based diagnostics, which allow doctors to tailor treatments and interventions to an individual’s unique genetic profile. Fetal aneuploidy confirmation testing enables personalized medicine by providing precise genetic information about the fetus, allowing clinicians to tailor prenatal care, risk management, and treatment decisions specifically to the individual genetic profile of each pregnancy. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the U.S. Food and Drug Administration (FDA) approved 16 new personalized therapies for patients with rare diseases, marking a substantial rise from the six approvals recorded in 2022. Therefore, the growth in personalized medicine is driving the growth of the fetal aneuploidy confirmation testing industry. The rising prevalence of chromosomal abnormalities is expected to propel the growth of the fetal aneuploidy confirmation testing market going forward. Chromosomal abnormalities are genetic disorders caused by changes in chromosome number or structure leading to conditions such as trisomies and other aneuploidies. The prevalence of chromosomal abnormalities is growing due to increasing maternal age, as older maternal age is associated with a higher risk of errors during cell division that lead to conditions such as trisomies and other aneuploidies. Fetal aneuploidy confirmation testing helps identify and confirm chromosomal abnormalities in the developing fetus by analyzing genetic material, enabling early diagnosis, informed clinical decisions, and timely management of conditions such as trisomies and other aneuploidies. For instance, in November 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, each year, approximately 5,700 babies are born with down syndrome in the United States, which corresponds to roughly 1 in every 640 births. Therefore, the rising prevalence of chromosomal abnormalities is driving the growth of the fetal aneuploidy confirmation testing industry.

Key Players In The Global Fetal Aneuploidy Confirmation Testing Market

Major companies operating in the fetal aneuploidy confirmation testing market are Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., SYNLAB AG, Myriad Genetics Inc., CapitalBio Technology Co. Ltd., BGI Genomics Co. Ltd., Centogene N.V., Yourgene Health plc, MedGenome Labs Ltd., Fulgent Genetics Inc., Annoroad Gene Technology Co. Ltd., CeGaT GmbH, LifeCodexx AG, Variantyx Inc., Igenomix S.L.U.

Regional Insights

North America was the largest region in the fetal aneuploidy confirmation testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Fetal Aneuploidy Confirmation Testing Market?

The fetal aneuploidy confirmation testing market consists of revenues earned by entities by providing services such as genetic counseling, diagnostic sampling procedures including amniocentesis and chorionic villus sampling, laboratory-based cytogenetic analysis, and rapid aneuploidy detection. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data And Analysis Are Included In The Fetal Aneuploidy Confirmation Testing Market Report 2026?

The fetal aneuploidy confirmation testing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the fetal aneuploidy confirmation testing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.